Author:
Parkinson Joanna,Chain Anne S.Y.,van der Graaf Piet H.,Visser Sandra A.G.
Reference191 articles.
1. Aarons L, Karlsson MO, Mentré F, Rombout F, Steimer JL, van Peer A COST B15 Experts (2001) Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci 13:115–122
2. Abrahamsson C, Dota C, Skallefell B, Carlsson L, Halawani D, Frison L, Berggren A, Edvardsson N, Duker G (2011) DeltaT50—a new method to assess temporal ventricular repolarization variability. J Electrocardiol 44(4):477.e1–477.e9
3. Adesanya CO, Yousuf KA, Co C, Gaur S, Ahmed S, Pothoulakis A, Suryaprasad A, Gupta S (2008) Is wider worse? QRS duration predicts cardiac mortality in patients with right bundle branch block. Ann Noninvas Electrocardiol 13(2):165–170
4. Ando KHT, Kanno A, Ikeda H, Imaizumi M, Shimizu N, Sakamoto K, Shin-ichi Kitani S, Yamamoto Y, Hizume S, Nakai K, Kitayama T, Yamamoto K (2005) QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 99:487–500
5. Anon (2005a) ICH S7B: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002841.pdf
. Accessed 1 Feb 2013
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献